TECR

Very-long-chain enoyl-CoA reductase · Q9NZ01 · TECR on Sugi Atlas →

0 patent compounds predicted against TECR, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to TECR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons PHASE4COMPLETED
Comparison of Coenzyme A and Pantethine Capsule for Safety and Efficacy On Patients With Hyperlipidemia PHASE3COMPLETED
Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia PHASE3COMPLETED
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis PHASE2UNKNOWN
Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects PHASE2COMPLETED
Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC PHASE2COMPLETED
The Effects of Coenzyme A on Serum Lipids in Patients With Hyperlipidemia PHASE2COMPLETED
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease PHASE2COMPLETED
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients PHASE2COMPLETED
Statin Intervention for Severe Early-Onset Placental Insufficiency. (STATIN-PRE Trial) PHASE2RECRUITING
NEO100 and High-Grade Meningioma PHASE2RECRUITING
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC PHASE1/PHASE2UNKNOWN
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
Fatty Acid Oxidation Defects and Insulin Sensitivity nanCOMPLETED
Compassionate Use of Triheptanoin (C7) for Inherited Disorders of Energy Metabolism nanNO_LONGER_AVAILABLE
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study nanCOMPLETED
11C-Acetate PET/CT Non-FDG-Avid Tumors nanUNKNOWN
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. nanCOMPLETED
Expanded Access to Triheptanoin nanAVAILABLE
Ekvasis of Atorvastatin (Antorcin®) Treatment in Patients With Acute Cardiovascular Events nanCOMPLETED
Lifestyle Intervention in Preparation for Pregnancy (LIPP) nanCOMPLETED
Mechanisms of Glucose Lowering Effect of Colesevelam HCl nanCOMPLETED
Screening of Healthy Adults for Genetic Variations That Control Fatty Acid Processing nanCOMPLETED
Effect of Atorvastatin on 5-Fluorouracil Induced Mucositis nanUNKNOWN
Novel Inhibitors of Lipolysis in the Treatment of Lipid a Glucose Metabolism in Obstructive Sleep Apnea Syndrome nanUNKNOWN
Epidemiology of Atherosclerosis nanCOMPLETED
Effect of Statin Preloading in STEMI in Improving PCI Outcomes nanUNKNOWN
Influence of Simvastatin on Apolipoprotein B-100 (apoB-100) Secretion nanCOMPLETED
Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN) nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a TECR binder may also engage these)

ProteinNameSimilarity
Q3ZCD7 1.000 Q3ZCD7 →
Q64232 0.995 Q64232 →
Q9CY27 0.993 Q9CY27 →
Q9H6U8 0.952 Q9H6U8 →
Q8VDI9 0.939 Q8VDI9 →
B1MTH4 0.935 B1MTH4 →
Q9JMF7 0.935 Q9JMF7 →
B2KI79 0.935 B2KI79 →
B0KWE9 0.934 B0KWE9 →
Q13888 0.933 Q13888 →
B0CM95 0.933 B0CM95 →
Q91ZH7 0.933 Q91ZH7 →
Q2TBV5 0.932 Q2TBV5 →
Q86YN1 0.932 Q86YN1 →
ERG28 Ergosterol biosynthetic protein 28 homolog 0.931 landscape →
Q6P1K8 0.930 Q6P1K8 →
Q5R589 0.930 Q5R589 →
Q1JQE6 0.928 Q1JQE6 →
NCEH1 Neutral cholesterol ester hydrolase 1 0.927 landscape →
Q5R8Y5 0.927 Q5R8Y5 →
Q8NFT2 0.925 Q8NFT2 →
Q9JIB4 0.925 Q9JIB4 →
PAICS Bifunctional phosphoribosylaminoimidazole carboxylase/phosphoribosylaminoimidazole succinocarboxamide synthetase 0.925 landscape →
Q8BWB6 0.924 Q8BWB6 →
A6QQ59 0.924 A6QQ59 →
Q9ERY9 0.923 Q9ERY9 →
A0JN27 0.923 A0JN27 →
O95406 0.922 O95406 →
P57791 0.922 P57791 →
Q5ZJH8 0.922 Q5ZJH8 →